Adel Mohammadzadeh

Adel Mohammadzadeh

Auto-generated profile, based on publicly available information

Adel Mohammadzadeh

Department of Immunology and genetic, Urmia University of Medical Sciences, Urmia, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in International Immunopharmacology
Verified
Journal Article
Closed access
AMAdel Mohammadzadeh
Adel Mohammadzadeh
APAli Akbar Pourfathollah
Ali Akbar Pourfathollah
SSSomayeh Shahrokhi
Somayeh Shahrokhi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi
SMSadegh Lotf Alah Moradi
Sadegh Lotf Alah Moradi
MSMasoud Soleimani
Masoud Soleimani

1 October 2018 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
AMAdel Mohammadzadeh
Adel Mohammadzadeh
IRIsa Abdi Rad
Isa Abdi Rad
BABabak Ahmadi-Salmasi
Babak Ahmadi-Salmasi

1 August 2016 in Clinical Immunology
Verified
Journal Article
Closed access
AMAdel Mohammadzadeh
Adel Mohammadzadeh
APAli Akbar Pourfathollah
Ali Akbar Pourfathollah
SSSomayeh Shahrokhi
Somayeh Shahrokhi
AFAli Fallah
Ali Fallah
MTMohammad Taher Tahoori
Mohammad Taher Tahoori
MSMasoud Soleimani
Masoud Soleimani

1 June 2019 in Immunology Letters
Verified
Journal Article
Closed access
SSSam Seydi Shirvani
Sam Seydi Shirvani
MNMohammad Nouri
Mohammad Nouri
ESEbrahim Sakhinia
Ebrahim Sakhinia
ZBZohreh Babaloo
Zohreh Babaloo
AMAdel Mohammadzaeh
Adel Mohammadzaeh
AKAlireza Khabbazi
Alireza Khabbazi

31 August 2011 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AMAdel Mohammadzadeh
Adel Mohammadzadeh
APAli Akbar Pourfathollah
Ali Akbar Pourfathollah
MTMohammad Taher Tahoori
Mohammad Taher Tahoori
SDSaeed Daneshmandi
Saeed Daneshmandi
LLLadan Langroudi
Ladan Langroudi
MAMasoumeh Akhlaghi
Masoumeh Akhlaghi

1 January 2018 in Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
AMAdel Mohammadzadeh
Adel Mohammadzadeh
SRSoheila Rezapour-Firouzi
Soheila Rezapour-Firouzi
SSShahram Shahabi
Shahram Shahabi
ATAli Asgar Tehrani
Ali Asgar Tehrani
FKFatemeh Kheradmand
Fatemeh Kheradmand
EMEbrahim Mazloomi
Ebrahim Mazloomi
The mammalian target of rapamycin (mTOR) has a fundamental role in the metabolism, growth, and regulation of the immune system. The interferon gamma (IFN-γ)derived from T helper 1 (Th1) cells is a prominent pro-inflammatory cytokine in multiple sclerosis (MS) and its animal model, the experimental autoimmune encephalomyelitis (EAE). Due to the exclusive role of rapamycin (RAPA) in mTOR complex 1 (mTORC1) inhibition, essentially Th1 differentiation and IFN-γ production, we evaluated the potential therapeutic effects of hemp seed/evening primrose oils (HSO/EPO) in comparison with RAPA administration in EAE. To evaluate the therapeutic effects of EPO/HSO supplement in comparison with RAPA, EAE was induced using myelin oligodendrocyte glycoprotein (MOG) peptide and complete Freund's adjuvant in C57BL/6 mice. The weight, clinical score, and histological findings were evaluated. Total mRNA was extracted from local lymph nodes and qRT-PCR was used for the purpose of the genes expression level of regulatory associated protein of TORC1 (RAPTOR) and IFN-γ. Our results indicated that the relative expression of RAPTOR and IFN-γ genes were significantly reduced in HSO/EPO, RAPA, and RAPA + HSO/EPO treated groups in comparison with the untreated group. Interestingly, histological findings have shown that the HSO/EPO treated group remarkably regenerated the myelin sheath, but this did not occur in the case of RAPA or combined RAPA and HSO/EPO treated groups. Our findings suggeste that HSO/HPO can be used as a potent immunomodulator and as a good candidate for re-myelination and downregulation of immune response for treatment of MS.